Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and clinical use. The primary purpose of this book is to summarize and present best practices in this field to date, and offer actionable information – and hopefully also inspiration – to move discovery and clinical application forward.
This latest volume in the Wiley-Blackwell series Translational Oncology (edited by Robert Bast, MD, and Ernest Hawk, MD, of the MD Anderson Cancer Center, and Maurie Markman, MD, of Cancer Treatment Centers of America) is organized into three sections: Section I lays the foundation for biomarker discovery, development and validation. Section II presents organ-specific topics relevant to the clinical needs in early detection, the natural history of the disease and associated evidence in support of biomarker research, an overview of the current state-of-the art in biomarker research, current progress toward bringing these biomarkers into clinical use and the future of biomarker-based screening and early detection for the respective organ type. Finally, Section III offers chapters that address the current screening strategies for selected organ types, discuss deficiencies with the present practice and identify clinical needs that may benefit from biomarker-based approaches.
